Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
…, M Delcroix, HA Ghofrani, D Huscher… - European …, 2017 - Eur Respiratory Soc
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry
MM Hoeper, D Huscher, HA Ghofrani… - International journal of …, 2013 - Elsevier
Background Originally reported to occur predominantly in younger women, idiopathic pulmonary
arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to …
arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to …
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary …
…, M Delcroix, HA Ghofrani, H Tiede, D Huscher… - Circulation, 2014 - Am Heart Assoc
Background— For almost 30 years, anticoagulation has been recommended for patients with
idiopathic pulmonary arterial hypertension (IPAH). Supporting evidence, however, is limited…
idiopathic pulmonary arterial hypertension (IPAH). Supporting evidence, however, is limited…
[HTML][HTML] COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
…, C Pausch, KM Olsson, D Huscher… - European …, 2022 - Eur Respiratory Soc
Background Risk stratification plays an essential role in the management of patients with
pulmonary arterial hypertension (PAH). The current European guidelines propose a three-…
pulmonary arterial hypertension (PAH). The current European guidelines propose a three-…
Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum
…, CD Vizza, G Staehler, L Bruch, D Huscher… - Journal of the American …, 2016 - jacc.org
Background : Pulmonary hypertension (PH) is hemodynamically classified as pre-capillary (as
seen in idiopathic pulmonary arterial hypertension [IPAH]) or post-capillary (as seen in …
seen in idiopathic pulmonary arterial hypertension [IPAH]) or post-capillary (as seen in …
Employment across chronic inflammatory rheumatic diseases and comparison with the general population.
W Mau, J Listing, D Huscher, H Zeidler… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: To compare labor force participation across chronic inflammatory rheumatic
diseases in order to assess the influence of the disease, disease duration, sex, education, and …
diseases in order to assess the influence of the disease, disease duration, sex, education, and …
[HTML][HTML] Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
…, RA Lewis, KM Olsson, D Huscher… - The Lancet …, 2022 - thelancet.com
Background Among patients meeting diagnostic criteria for idiopathic pulmonary arterial
hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion …
hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion …
[HTML][HTML] Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
…, E Grünig, H Klose, G Staehler, D Huscher… - The Journal of Heart and …, 2020 - Elsevier
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with
pre-capillary pulmonary hypertension of unknown origin. There is considerable variability …
pre-capillary pulmonary hypertension of unknown origin. There is considerable variability …
[HTML][HTML] Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
…, E Grünig, G Staehler, D Huscher… - European …, 2022 - Eur Respiratory Soc
Background Since 2015, the European pulmonary hypertension guidelines recommend the
use of combination therapy in most patients with pulmonary arterial hypertension (PAH). …
use of combination therapy in most patients with pulmonary arterial hypertension (PAH). …
[HTML][HTML] Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients
…, C Meisel, LG Hanitsch, MO Becker, D Huscher… - Arthritis research & …, 2009 - Springer
Introduction Interstitial lung disease (ILD) is a frequent manifestation of systemic sclerosis (SSc),
and cytokines can contribute to the disease pathology. The aim of the current study was …
and cytokines can contribute to the disease pathology. The aim of the current study was …